Alpha Teknova, Inc. filings document the company’s operating results, governance matters and public-company disclosures as a producer of critical reagents for life-sciences customers. Form 8-K reports furnish quarterly and annual earnings releases, revenue by Lab Essentials and Clinical Solutions, guidance, cash metrics, borrowings and related exhibits.
Proxy and current-report filings cover director elections, auditor ratification, annual meeting vote results, board and stockholder procedures, and amendments to the company’s Code of Business Conduct and Ethics. The filing record also identifies Teknova’s common-stock issuer status, emerging growth company disclosure and corporate-governance framework.
Alpha Teknova, Inc. (TKNO) is offering shares of its common stock, with underwriters holding a 30-day option to purchase additional shares at the public offering price less discounts and commissions. The company intends to use net proceeds for general corporate purposes, potentially including repayment of part of its outstanding debt, and may also use them for working capital; management has broad discretion over their use.
For the third quarter of 2026, preliminary estimates put revenue 19%–21% above the prior-year quarter, gross margin expansion at 500–700 basis points, and Adjusted EBITDA improvement at at least 25%. Estimated Adjusted EBITDA is a loss of $1.0 million to $1.2 million, while estimated net loss is $3.494 million to $3.694 million. These unaudited estimates are subject to completion of closing procedures and quarterly review and may change materially.
Common shares outstanding were 53,702,534 as of September 30, 2026. Separately, the company may sell up to $50.0 million under its sales agreement after the offering lock-up expires or is waived, once a new prospectus or registration statement is filed.
Alpha Teknova, Inc. produces critical reagents for life‑science research, diagnostics, and therapeutics. For the quarter ended June 30, 2026, revenue was $12,185 thousand, up 18.5% year over year, with gross margin improving to 40.1%. Lab Essentials and Clinical Solutions each grew 17.9%.
The company reported a net loss of $3,170 thousand for the quarter and $7,725 thousand for the first half, modestly better than 2025, as operating expenses grew only 3.4% year to date. Operating cash use fell to $3,830 thousand for the first half from $6,204 thousand a year earlier.
Cash and cash equivalents were $6,004 thousand and short‑term U.S. Treasury investments $11,432 thousand, against $13,218 thousand of long‑term debt, all under a credit facility that requires at least $8.0 million of cash and investments. One distributor customer represented 24% of Q2 revenue, and key suppliers each exceeded 20% of purchases. New risk disclosures highlight potential operational, regulatory, and cybersecurity exposures from increased use of artificial intelligence in operations.
Alpha Teknova reported Q2 2026 revenue of $12.2 million, up 18% from $10.3 million a year earlier, with growth across Lab Essentials and Clinical Solutions. Gross profit rose to $4.9 million and gross margin improved to 40.1% from 38.7%.
Net loss narrowed to $3.2 million, or $0.06 per share, versus $3.6 million, or $0.07 per share. Adjusted EBITDA was a loss of $0.7 million. Free Cash Outflow improved to $0.6 million from $2.3 million, as cash used in operating activities declined to $0.5 million.
Total cash and short-term investments were $17.4 million and total borrowings were $13.2 million at June 30, 2026. Management raised 2026 revenue guidance to $45–$47 million, now expecting Free Cash Outflow of less than $8 million, and launched its AI-powered Build-Tek custom configurator.
Alpha Teknova, Inc. director Martha J. Demski reported an internal reclassification of 12,000 shares of Common Stock, transferring them from her individual account to a trust for which she serves as trustee. The move involved no consideration, was not an open-market trade, and caused no change in her beneficial ownership.
Alpha Teknova, Inc. director Alexander Vos received a grant of options covering 55,000 shares of common stock as equity compensation. These non-qualified stock options have an exercise price of $5.37 per share and expire on June 1, 2036. The award vests in full on the first anniversary of the grant date, meaning Vos must remain in service for one year before any options become exercisable. This is a compensation-related grant, not an open-market purchase or sale of shares.
Alpha Teknova, Inc. director Brett Robertson received a grant of non-qualified stock options covering 55,000 shares of common stock. The options have an exercise price of $5.37 per share and expire on June 1, 2036. According to the disclosure, all 55,000 shares subject to the option will vest on the first anniversary of the grant date. After this grant, the filing shows Robertson holding options for 55,000 underlying shares directly.
Alpha Teknova, Inc. director Martha J. Demski received a grant of non-qualified stock options covering 55,000 shares of common stock. The options have an exercise price of $5.37 per share and expire on June 1, 2036. According to the footnote, all 55,000 shares underlying the option vest on the first anniversary of the grant date, so she must remain eligible until then to receive the full award.
Alpha Teknova, Inc. reported governance updates and voting results from its 2026 Annual Meeting of Stockholders. Director Irene Davis chose not to stand for re-election and retired from the Board and its Nominating and Corporate Governance Committee for personal and professional reasons, with no disagreement related to company matters.
Effective June 1, 2026, the Board reduced its size from eight to seven directors and decreased the number of Class II directors from three to two, and appointed existing director Ms. Demski to the Nominating and Corporate Governance Committee. At the meeting, 47,821,520 shares, representing 89.20% of common stock outstanding as of the record date, were represented.
Stockholders elected Class II directors J. Matthew Mackowski and Brett Robertson to serve until the 2029 annual meeting and ratified Grant Thornton LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Alpha Teknova, Inc. reported Q1 2026 revenue of $11.1 million, up from $9.8 million a year ago, driven by growth in both Lab Essentials and a strong 84.6% increase in Clinical Solutions. Gross margin improved to 34.2% from 30.7%, reflecting better profitability on higher volumes.
The company still posted a net loss of $4.6 million, similar to Q1 2025, though operating loss narrowed slightly. Teknova ended the quarter with $17.8 million in cash, cash equivalents, and short‑term investments, $24.8 million of working capital, and $13.2 million of term debt, and remained in compliance with loan covenants.
Alpha Teknova reported first quarter 2026 revenue of $11.1 million, up 13% from $9.8 million a year earlier, driven by growth in both major product lines. Lab Essentials revenue rose to $8.4 million, while Clinical Solutions nearly doubled to $2.1 million.
Gross margin improved to 34.2% from 30.7% as gross profit increased to $3.8 million. Operating expenses were $8.1 million, resulting in a net loss of $4.6 million, or $0.08 per share, similar to the prior year. Adjusted EBITDA was negative $2.0 million and Free Cash Outflow was $3.6 million, both better than 2025 levels.
The company ended the quarter with $17.8 million in cash and short-term investments and $13.2 million of total borrowings. Teknova reaffirmed its 2026 outlook for revenue of $42–44 million and expects full-year Free Cash Outflow of less than $10 million. The board also approved a refreshed Code of Business Conduct and Ethics focused on updates, clarifications, and administrative improvements.